Please assess the completion status of the following clinical trial:

Trial Title: Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with unresectable cancer for which there are genomic drivers with corresponding Food and Drug Administration (FDA) approved or experimental drugs available, e.g. non-small cell lung cancer; and/or patients with histologically confirmed metastatic malignancy that have failed standard treatment or cannot tolerate standard treatment as deemed by the treating physician~* Malignancy must be measureable as per appropriate guidelines~* Patients who are willing to provide a specimen for genomic sequencing~  * Preferred method:~    * Tumor cell sample available and of sufficient quantity in the Tumor Tissue Shared Resource or patients who are willing to undergo additional tissue collection for tumor genomic sequencing through FoundationOne; available specimens must have been harvested within two years to be eligible~ * Alternative method:~    * Patients who are unwilling or unable to provide a tumor tissue sample and who undergoes Guardant360 sequencing may be considered eligible by the treating physician~ * Patients who have already had their specimens sent for genomic sequencing are eligible provided they have not received their sequencing results at the time of enrollment~* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2~* Absence of clinically relevant liver or kidney failure as deemed by the treating physician~* Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document~Exclusion Criteria:~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diminished mental capacity or psychiatric illness/social situations that would limit compliance with study requirements~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (precision medicine) (Type: EXPERIMENTAL): Patients receive treatment based on the results of their genomic sequencing analyses.

Based on this trial design, predict the completion outcome and termination type (if applicable).